Trial Profile
A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects With Early Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jun 2019
Price :
$35
*
At a glance
- Drugs Cinpanemab (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biogen
- 17 Jun 2019 Results published in the Movement Disorders
- 27 Apr 2018 Preliminary results (n=18) presented at the 70th Annual Meeting of the American Academy of Neurology.
- 17 Apr 2018 According to a Biogen media release, data from this study will be presented at the 70th annual meeting of the American Academy of Neurology (AAN) 2018.